Humacyte, a clinical-stage biotech platform company, has agreed to merge with blank check company Alpha Healthcare Acquisition Corp. (AHAC), in a deal that values the combined firm at $1.1 billion. Based in Durham, North Carolina, Humacyte is focused on developing bioengineered human tissue that can be universally implantable at commercial scale. Rajiv Shukla – Chairman […]
Humacyl vascular trauma trial : Humacyte, a regenerative medical technology company, has started a phase 2 clinical trial of its investigational human acellular vessel (HAV) – Humacyl for vascular replacement or reconstruction in patients suffering from life- or limb-threatening vascular trauma. Humacyl is a bioengineered human acellular vessel which has been designed to significantly improve […]
Continue reading …